• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Allogene Therapeutics Inc.

    5/13/25 11:44:13 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Allogene Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    019770106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    019770106


    1Names of Reporting Persons

    Capital World Investors
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    12,265,330.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    12,265,330.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,265,330.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Allogene Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    210 East Grand Avenue, South San Francisco, CA 94080, United States of America
    Item 2. 
    (a)Name of person filing:

    Capital World Investors
    (b)Address or principal business office or, if none, residence:

    333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071
    (c)Citizenship:

    N/A
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    019770106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    12,265,330 ** **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 12,265,330 shares or 5.6% of the 217,264,738 shares believed to be outstanding.
    (b)Percent of class:

    5.6  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    12,265,330

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    12,265,330

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    SMALLCAP World Fund, Inc.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Capital World Investors
     
    Signature:Jae Won Chung
    Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
    Date:05/02/2025
    Get the next $ALLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALLO

    DatePrice TargetRatingAnalyst
    5/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/14/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    8/8/2024$13.00 → $11.00Outperform
    Oppenheimer
    5/31/2024$11.00Overweight
    Piper Sandler
    1/5/2024Mkt Outperform → Mkt Perform
    JMP Securities
    1/5/2024Buy → Neutral
    Guggenheim
    12/8/2023$7.00Buy
    Citigroup
    12/8/2023Buy
    Citigroup
    More analyst ratings

    $ALLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Allogene downgraded by Citizens JMP

      Citizens JMP downgraded Allogene from Mkt Outperform to Mkt Perform

      5/14/25 8:54:15 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene upgraded by Citizens JMP with a new price target

      Citizens JMP upgraded Allogene from Mkt Perform to Mkt Outperform and set a new price target of $5.00

      3/14/25 7:12:11 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer resumed coverage on Allogene with a new price target

      Oppenheimer resumed coverage of Allogene with a rating of Outperform and set a new price target of $11.00 from $13.00 previously

      8/8/24 7:10:59 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Finance Yoshiyama Annie sold $13,537 worth of shares (9,601 units at $1.41), decreasing direct ownership by 7% to 130,663 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      4/23/25 5:28:51 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Chang David D sold $91,469 worth of shares (46,668 units at $1.96), decreasing direct ownership by 0.88% to 5,276,569 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      3/18/25 5:30:50 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, Chief Technical Officer Beneski Benjamin Machinas sold $10,839 worth of shares (5,488 units at $1.98), decreasing direct ownership by 2% to 218,507 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      3/18/25 5:28:04 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ALLO
    SEC Filings

    See more
    • Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

      SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four upcoming investor conferences in May and June. TD Cowen's 6th Annual Oncology Innovation Summit: Insights for ASCO & EHATuesday, May 279:30AM PT/12:30PM ET Jefferies Global Healthcare ConferenceWednesday, June 41:55PM PT/4:55PM ET Goldman Sachs 46th Annual Global Healthcare ConferenceTuesday, June 105:00AM PT/8:00AM ET Oppenheimer Innovators in I&I SummitWednesday, June 259:45AM PT/12:45PM ET

      5/23/25 8:30:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

      SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago, Illinois. An oral presentation will feature ALLO-316, an investigational AlloCAR T product targeting CD70. ALLO-316 is currently being studied in patients with advanced or metastatic renal cell carcinoma (RCC). Leveraging the proprietary Dagger® technology

      5/22/25 5:17:55 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

      Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from InvestigatorsLymphodepletion Selection and Futility Analysis Shifted to 1H 2026 in Part Due to Site-Related Factors that Impacted Expected Pace of Screening Immediately Following Site ActivationOver 250 Patients Consented for MRD Screening to Date, with Nearly Half in the Last Three Months and Awaiting Completion of 1L Treatment as Earliest Activated Sites Build MomentumInternational Expansion of ALPHA3 Trial to Begin with Site Activations in Canada in Q2 2025 Phase 1 RESOLUTION Trial with A

      5/13/25 4:05:00 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Allogene Therapeutics Inc.

      10-Q - Allogene Therapeutics, Inc. (0001737287) (Filer)

      5/13/25 4:07:36 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)

      5/13/25 4:06:51 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Allogene Therapeutics Inc.

      SCHEDULE 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)

      5/13/25 11:44:13 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Allogene Therapeutics Inc.

      SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

      11/12/24 1:26:25 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Allogene Therapeutics Inc.

      SC 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)

      11/4/24 10:57:36 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)

      SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

      2/14/24 4:36:10 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Belldegrun Arie was granted 344,828 shares and bought $4,999,997 worth of shares (1,724,137 units at $2.90) (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      5/20/24 9:33:32 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Parker Geoffrey M. bought $683 worth of shares (190 units at $3.60), increasing direct ownership by 0.02% to 819,590 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      3/6/24 9:52:06 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Leadership Updates

    Live Leadership Updates

    See more

    $ALLO
    Financials

    Live finance-specific insights

    See more
    • Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

      SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog

      10/22/24 4:05:00 PM ET
      $ALLO
      $ARTV
      $CDXS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Chemicals
      Industrials
    • Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company's financial operations and business strategy and will serve as a member of the Leadership Team. "Geoff's extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities," said David Chang, M.D., Ph.D.

      10/16/23 8:30:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics Appoints Earl Douglas as General Counsel

      SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General Counsel. Mr. Douglas will oversee all aspects of the Company's legal function and serve as a member of the Leadership Team. "We are excited to welcome Earl who brings a tenure of experience guiding publicly-traded biotech companies on complex legal issues, corporate strategy and transactions," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "I also want to th

      8/14/23 8:30:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

      Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from InvestigatorsLymphodepletion Selection and Futility Analysis Shifted to 1H 2026 in Part Due to Site-Related Factors that Impacted Expected Pace of Screening Immediately Following Site ActivationOver 250 Patients Consented for MRD Screening to Date, with Nearly Half in the Last Three Months and Awaiting Completion of 1L Treatment as Earliest Activated Sites Build MomentumInternational Expansion of ALPHA3 Trial to Begin with Site Activations in Canada in Q2 2025 Phase 1 RESOLUTION Trial with A

      5/13/25 4:05:00 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

      Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company's website at www.all

      5/6/25 8:30:00 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

      Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activation and Patient EnrollmentLymphodepletion Selection and Futility Analysis Anticipated Around Mid-2025Primary EFS Data Expected Around YE 2026 with Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Secured Investigational New Drug (IND) FDA Clearance for the RESOLUTION Basket Trial in RheumatologyTrial Initiation Targeted for Mid-2025; Proof-of-Concept Data Expected Around YE 2025 ALLO-316 in Renal Cell Carcinoma (RCC) Presented Posi

      3/13/25 4:02:00 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care